Pages that link to "Q73648001"
Jump to navigation
Jump to search
The following pages link to Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients (Q73648001):
Displaying 50 items.
- Capecitabine in the management of colorectal cancer (Q24633039) (← links)
- Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study (Q25257445) (← links)
- Systemic Chemotherapy in Advanced Pancreatic Cancer (Q26750440) (← links)
- Thymidine Phosphorylase in Cancer; Enemy or Friend? (Q26795650) (← links)
- Review of systemic therapies for locally advanced and metastatic rectal cancer (Q27021105) (← links)
- Management of locally advanced and metastatic colon cancer in elderly patients (Q27026129) (← links)
- 5-Fluorouracil: mechanisms of action and clinical strategies (Q28201937) (← links)
- Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer (Q28366029) (← links)
- Chemoradiotherapy for gastrointestinal cancers (Q30436646) (← links)
- Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials (Q30673291) (← links)
- Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials (Q30913489) (← links)
- Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer (Q33349114) (← links)
- Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial (Q33361603) (← links)
- Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy (Q33364558) (← links)
- A phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancer (Q33366181) (← links)
- Phase one dose finding study of capecitabine (Xeloda), radiotherapy and cisplatin in the treatment of locally advanced squamous cervical cancer (Q33366314) (← links)
- A Phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma. (Q33368148) (← links)
- Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine (Q33370303) (← links)
- XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer (Q33370632) (← links)
- Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. (Q33376718) (← links)
- Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial (Q33377361) (← links)
- Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma (Q33388581) (← links)
- A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract (Q33430668) (← links)
- Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer (Q33620052) (← links)
- Prospective phase II study of preoperative chemoradiation with capecitabine in locally advanced rectal cancer (Q33746816) (← links)
- Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome (Q33853588) (← links)
- Targeting cancers in the gastrointestinal tract: role of capecitabine (Q33916021) (← links)
- A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors (Q33919101) (← links)
- A phase I study of an oral simulated FOLFOX with high dose capecitabine (Q33973344) (← links)
- Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years (Q34008793) (← links)
- Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma (Q34010159) (← links)
- Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer (Q34168931) (← links)
- Clinical pharmacokinetics of capecitabine (Q34207262) (← links)
- Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer (Q34225660) (← links)
- The role of capecitabine in locally advanced rectal cancer treatment: an update (Q34276823) (← links)
- Oncologic Outcome after Cessation or Dose Reduction of Capecitabine in Patients with Colon Cancer (Q34385292) (← links)
- Recent advances in the management of colorectal cancer (Q34447526) (← links)
- Capecitabine: an evidence-based review of its effectiveness in the treatment of carcinoma of the pancreas (Q34449812) (← links)
- Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer (Q34481305) (← links)
- Systemic treatment of colorectal cancer (Q34615998) (← links)
- A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer (Q34682635) (← links)
- Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer? (Q34711507) (← links)
- Personalized Colon Cancer Care in 2010 (Q34731381) (← links)
- Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study (Q34886764) (← links)
- The dual role of thymidine phosphorylase in cancer development and chemotherapy (Q34980526) (← links)
- Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer (Q35032865) (← links)
- The Medical Management of Pancreatic Cancer: A Review (Q35108011) (← links)
- Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial (Q35125643) (← links)
- Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience (Q35188403) (← links)
- Pilot study investigating the prognostic significance of thymidine phosphorylase expression in patients with metastatic breast cancer: a single institution retrospective analysis (Q35541901) (← links)